To make progress, we must talk openly about suicide

Our purpose

COMPASS's CPT III code

COMPASS's highlights from 2022

COMPASS's Phase 2b data published in the New England Journal of Medicine

COMPASS's Phase 3 programme

COMPASS's impact strategy

World Quality Week at COMPASS

World Quality Week at COMPASS

World Quality Week at COMPASS

COMPASS Pathways' phase 2b data published in the New England Journal of Medicine

Scott Aaronson on COMPASS Pathways' phase 2b trial

World Mental Health Day 2022: our CEO's vision for the future

Introducing Kabir Nath, COMPASS Pathways' new CEO

Dr Guy Goodwin on COMPASS's trial of COMP360 psilocybin therapy in anorexia nervosa

Dr Walter Kaye on COMPASS's trial of COMP360 psilocybin therapy in anorexia nervosa

Dr Hubertus Himmerich on COMPASS's trial of COMP360 psilocybin therapy in anorexia nervosa

COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults

Living with treatment-resistant depression: Dee’s advice for others

Living with treatment-resistant depression: Dee’s story

Living with treatment-resistant depression: Eric’s story

Anne Cooke on the British Neuroscience Association’s Scholars programme

Psychologist Nadav Liam Modlin on the Importance of Set and Setting in Psilocybin Therapy

Professor Allan Young on the launch of The Centre for Mental Health Research and Innovation

David Bradley on the launch of The Centre for Mental Health Research and Innovation

Preparing for COMP360 psilocybin therapy

How psilocybin works

DBSA: Living with treatment-resistant depression

Dr Guy Goodwin on COMP360 Psilocybin Therapy and SSRIs

Allan Young on COMPASS’s Phase IIb Trial: Psilocybin Therapy for Treatment-Resistant Depression